BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

861 related articles for article (PubMed ID: 9761434)

  • 1. Advantage of post-operative oral administration of UFT (tegafur and uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC).
    Tanaka F; Miyahara R; Ohtake Y; Yanagihara K; Fukuse T; Hitomi S; Wada H
    Eur J Cardiothorac Surg; 1998 Sep; 14(3):256-62; discussion 263-4. PubMed ID: 9761434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur + Uracil) in patients with p-stage I nonsmall-cell lung cancer.
    Nakagawa T; Tanaka F; Takata T; Matsuoka K; Miyahara R; Otake Y; Yanagihara K; Fukushimab M; Wada H
    J Surg Oncol; 2002 Oct; 81(2):87-92. PubMed ID: 12355409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postoperative adjuvant chemotherapy for non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery. The Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy.
    Wada H; Tanaka F; Hitomi S
    Oncology (Williston Park); 1997 Sep; 11(9 Suppl 10):98-102. PubMed ID: 9348578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiogenesis and the efficacy of postoperative administration of UFT in pathologic stage I non-small cell lung cancer.
    Tanaka F; Yanagihara K; Otake Y; Miyahara R; Wada H
    Cancer Sci; 2004 Apr; 95(4):371-6. PubMed ID: 15072598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial of postoperative UFT therapy in p stage I, II non-small cell lung cancer: North-east Japan Study Group for Lung Cancer Surgery.
    Endo C; Saito Y; Iwanami H; Tsushima T; Imai T; Kawamura M; Kondo T; Koike K; Handa M; Kanno R; Fujimura S;
    Lung Cancer; 2003 May; 40(2):181-6. PubMed ID: 12711119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer: the West Japan Study Group for Lung Cancer Surgery (WJSG)--the 4th study.
    Nakagawa M; Tanaka F; Tsubota N; Ohta M; Takao M; Wada H;
    Ann Oncol; 2005 Jan; 16(1):75-80. PubMed ID: 15598942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postoperative adjuvant chemotherapy with PVM (Cisplatin + Vindesine + Mitomycin C) and UFT (Uracil + Tegaful) in resected stage I-II NSCLC (non-small cell lung cancer): a randomized clinical trial. West Japan Study Group for lung cancer surgery (WJSG).
    Wada H; Miyahara R; Tanaka F; Hitomi S
    Eur J Cardiothorac Surg; 1999 Apr; 15(4):438-43. PubMed ID: 10371118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A small randomized phase III single-center trial on postoperative UFT administration in patients with completely resected non-small cell lung cancer.
    Ueda H; Sakada T; Kuwahara M; Motohiro A
    Anticancer Drugs; 2004 Jan; 15(1):29-33. PubMed ID: 15090740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery.
    Wada H; Hitomi S; Teramatsu T
    J Clin Oncol; 1996 Apr; 14(4):1048-54. PubMed ID: 8648356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of postoperative adjuvant therapy for resected non-small cell lung cancer--an evidence-based review].
    Tanaka F; Wada H
    Gan To Kagaku Ryoho; 2006 Mar; 33(3):300-6. PubMed ID: 16531708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised study of adjuvant chemotherapy for completely resected p-stage I-IIIA non-small cell lung cancer.
    Nakagawa K; Tada H; Akashi A; Yasumitsu T; Iuchi K; Taki T; Kodama K;
    Br J Cancer; 2006 Oct; 95(7):817-21. PubMed ID: 16969350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Multicenter Randomized Controlled Study of Paclitaxel plus Carboplatin versus Oral Uracil-Tegafur as the Adjuvant Chemotherapy in Resected Non-Small Cell Lung Cancer.
    Toyooka S; Okumura N; Nakamura H; Nakata M; Yamashita M; Tada H; Kajiwara S; Watanabe N; Okada M; Sakamoto J; Aoe M; Soh J; Miyoshi S; Hotta K; Matsuo K; Date H
    J Thorac Oncol; 2018 May; 13(5):699-706. PubMed ID: 29505900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant chemotherapy for completely resected non-small-cell lung cancer.
    Suehisa H; Toyooka S
    Acta Med Okayama; 2009 Oct; 63(5):223-30. PubMed ID: 19893597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur+uracil) in patients with non-small cell lung cancer.
    Miyoshi T; Kondo K; Toba H; Yoshida M; Fujino H; Kenzaki K; Sakiyama S; Takehisa M; Tangoku A
    Anticancer Res; 2007; 27(4C):2641-8. PubMed ID: 17695427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Adjuvant chemotherapy for non-small cell lung cancer].
    Otake Y; Tanaka F; Wada H; Hitomi S
    Gan To Kagaku Ryoho; 1997 Aug; 24(10):1245-51. PubMed ID: 9279343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postoperative adjuvant cisplatin, vindesine, plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer.
    Imaizumi M;
    Lung Cancer; 2005 Jul; 49(1):85-94. PubMed ID: 15949594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A feasibility study of postoperative adjuvant chemotherapy with fluoropyrimidine S-1 in patients with stage II-IIIA non-small cell lung cancer.
    Tsuboi M; Kondo K; Takizawa H; Kawakita N; Sawada T; Toba H; Kawakami Y; Yoshida M; Ishikura H; Kimura S; Tangoku A
    J Med Invest; 2018; 65(1.2):90-95. PubMed ID: 29593202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of pathological stage and histological subtype on clinical outcome of adjuvant chemotherapy of paclitaxel plus carboplatin versus oral uracil-tegafur for non-small cell lung cancer: subanalysis of SLCG0401 trial.
    Soh J; Toyooka S; Okumura N; Nakamura H; Nakata M; Yamashita M; Sakamoto J; Aoe M; Hotta K; Morita S; Date H
    Int J Clin Oncol; 2019 Nov; 24(11):1367-1376. PubMed ID: 31312931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single-arm, phase 2 study of adjuvant chemotherapy with oral tegafur-uracil for pathologically lymphovascular invasion positive stage IA non-small cell lung cancer: LOGIK0602 study.
    Tsuchiya T; Kamohara R; Muraoka M; Nagayasu T; Saeki S; Takenoyama M; Suzuki M; Inada K; Tokunaga S; Hayashi T; Urabe S; Koga T; Akamine S; Sugio K
    BMC Cancer; 2020 Dec; 20(1):1192. PubMed ID: 33276755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III study of adjuvant gemcitabine compared with adjuvant uracil-tegafur in patients with completely resected pathological stage IB-IIIA non-small cell lung cancer (WJTOG0101).
    Yamaguchi M; Tada H; Mitsudomi T; Seto T; Yokoi K; Katakami N; Nakagawa K; Oda M; Ohta M; Sawa T; Yamashita M; Iked N; Saka H; Higashiyama M; Nomori H; Semba H; Negoro S; Chiba Y; Shimokawa M; Fukuoka M; Nakanishi Y;
    Int J Clin Oncol; 2021 Dec; 26(12):2216-2223. PubMed ID: 34463869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.